Predictive Safety Testing Consortium have proposed glutamate dehydrogenase (GLDH) as a more liver-specific biomarker for ...
Researchers from Critical Path Institute’s Predictive Safety Testing Consortium have proposed glutamate dehydrogenase (GLDH) as a more liver-specific biomarker for detecting liver injury, supporting ...
The U.S. Food and Drug Administration's (FDA) Biomarker Qualification Program (BQP) is currently reviewing C-Path's Full Qualification Package (FQP) to qualify GLDH as a liver safety biomarker. The ...